RETRACTED ARTICLE: Prevention of PONV with granisetron, droperidol and metoclopramide in female patients with history of motion sickness

  • Yoshitaka Fujii
  • Hidcnori Toyooka
  • Hiroyoshi Tanaka
Reports of Investigation



Motion sickness is one of the patient-related factors associated with postoperative nausea and vomiting (PONV). This study was undertaken to assess the efficacy of granisetron, droperidol and metoclopramide for preventing PONV in female patients with a history of motion sickness undergoing major gynaecological surgery.


In a prospective, randomized, placebo-controlled, double-blind study. 120 patients received either 1.25 mg dropendol. 10 mg metoclopramide, 40 μkg granisetron or placebo (saline)iv immediately before induction of anaesthesia. A standardized anaesthetic technique and postoperative analgesia were used in all patients. During the first 24 hr after anaesthesia, the incidence of PONV and adverse events were recorded by nursing-staff.


The treatment groups were similar for patient demographics, types of surgery, anaesthetics administered and opioid given. The incidence of PONV was 70%, 50%. 57% and 23% in the placebo, droperidol, metoclopramide and granisetron groups, respectively (P < 0.05; overall χ2 test). No difference in the incidence of adverse events was observed in either group.


Granisetron is a better prophylactic antiemetic than dropendol or metoclopramide in female patients with a history of motion sickness undergoing major gynaecological surgery.



Le mal des transports constitue un facteur prédisposant aux nausées et aux vomissements postopératoires (NVPO). Cette étude visait à étudier l’efficacité du granisetron, du dropéridol et de la métoclopramide administrés pour la prévention des NVPO chez des opérées pour une intervention chirurgicale gynécologique majeure.


Étude prospective, aléatoire, contrôlée par placebo et en double aveugle. Cent vingt patientes ont reçu soit dropéridol 1.25 mg, soit métoclopramide 10 mg, soit granisetron 40μg·k ou un placeboiv immédiatement avant l’induction de l’anesthésie. La technique anesthésique et l’analgésie postopératoire étaient standardisées pour toutes les patientes. Pendant les premières 24 h postopératoires. le personnel infirmier notait l’incidence des NVPO et des effets secondaires.


Les groupes etaient identiques sous l’aspect de la démographie, du type de chirurgie, de l’anesthésique et du morphmique administré. L’incidence des NVPO était de 70%. 50%. 57% et de 23% respectivement pour les groupes placebo, dropéridol, métoclopramide et granisetron (P < 0.05: test chi carré). L’incidence des effets secondaires n’a pas différé entre les groupes.


Le granisetron protège mieux des séquelles émétiques que le dropéndol ou la métoclopramide les patientes possédant des antécédents du mal des transport opérées pour une chirurgie gynécologique majeure.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992; 77: 162–84.PubMedCrossRefGoogle Scholar
  2. 2.
    Kamath B, Curran J, Hawkey C, et al. Anaesthesia, movement and emesis. Br J Anaesth 1990; 64: 728–30.PubMedCrossRefGoogle Scholar
  3. 3.
    Fujii T, Toyooka H, Tanaka H. Antiemetic effects of granisetron on postoperative nausea and vomiting in patients with and without motion sickness. Can J Anaesth 1996; 43: 110–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Bermudez J, Boyle EA, Miner WD, Sanger GJ. The antiemetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer 1988; 58: 644–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Fujii Y, Tanaka H, Toyooka H. Reduction of postoperative nausea and vomiting with granisetron. Can J Anaesth 1994; 41: 291–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Carmichael J, Cantwell BMJ, Edwards CM, et al. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation of anti-emetic response. Cancer Chemother Pharmacol 1989; 24: 45–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Furue H, Oota K, Taguchi T, Niitani H. Clinical evaluation of granisetron against nausea and vomiting induced by anticancer drugs. (I) Optimal dose-finding study (Japanese). J Clin Ther Med 1990; 6: 49–61.Google Scholar
  8. 8.
    Fujii Y, Tanaka H, Toyooka H. Optimal anti-emetic dose of granisetron for preventing postoperative nausea and vomiting. Can J Anaesth 1994; 41: 794–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Tarker TE, McTavisb D. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy. Drugs 1994; 48: 761–93.CrossRefGoogle Scholar
  10. 10.
    Korttila K, Kauste A, Auvinen J. Comparison of domperidone, droperidol, and metoclopramide in the prevention and treatment of nausea and vomiting after balanced general anesthesia. Anesth Analg 1979; 58: 396–400.PubMedCrossRefGoogle Scholar
  11. 11.
    Cohen SE, Woods WA, Wyner J. Antiemetic efficacy of droperidol and metoclopramide. Anesthesiology 1984; 60: 67–9.PubMedCrossRefGoogle Scholar

Copyright information

© Canadian Anesthesiologists 1997

Authors and Affiliations

  • Yoshitaka Fujii
    • 1
  • Hidcnori Toyooka
    • 1
  • Hiroyoshi Tanaka
    • 2
  1. 1.Department of AnaesthesiologyUniversity of Tsukuba Institute of Clinical MedicineIbarakiJapan
  2. 2.Department of AnaesthesiologyToride Kyodo General HospitalIbarakiJapan

Personalised recommendations